June 4, 2021 – The U.S. FDA has approved Tembexa® (brincidofovir), manufactured by Chimerix, to treat
smallpox. Although naturally occurring smallpox has been eradicated since 1980
June 4, 2021 – The U.S. FDA has approved Ryplazim® (plasminogen, human-tvmh), manufactured by
Liminal BioSciences, to treat plasminogen deficiency type 1 (hypoplasminogenemia)
June 2, 2021 – The U.S. FDA has approved Brexafemme® (ibrexafungerp), manufactured by Scynexis, to
treat vulvovaginal candidiasis (VVC) in adult and postmenarchal
June 1, 2021 – The U.S. FDA has approved an expanded plaque psoriasis indication for Cosentyx®
(secukinumab), manufactured by Novartis. The drug is now indicated to
June 1, 2021 – The U.S. FDA has approved Lybalvi TM (olanzapine/samidorphan) tablets, manufactured by
Alkermes, for the following indications for adult patients
June 1, 2021 – The U.S. FDA has granted accelerated approval to TruseltiqTM (infigratinib), manufactured
by BridgeBio and Helsinn Therapeutics, to treat adults who have previously
May 28, 2021 – The U.S. FDA has approved an expanded indication for Zipsor® (diclofenac potassium),
manufactured by Assertio Therapeutics, to provide relief of mild to